Martin Hegen

4.5k total citations
35 papers, 2.3k citations indexed

About

Martin Hegen is a scholar working on Oncology, Molecular Biology and Rheumatology. According to data from OpenAlex, Martin Hegen has authored 35 papers receiving a total of 2.3k indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Oncology, 13 papers in Molecular Biology and 11 papers in Rheumatology. Recurrent topics in Martin Hegen's work include Peptidase Inhibition and Analysis (10 papers), Rheumatoid Arthritis Research and Therapies (10 papers) and Cytokine Signaling Pathways and Interactions (10 papers). Martin Hegen is often cited by papers focused on Peptidase Inhibition and Analysis (10 papers), Rheumatoid Arthritis Research and Therapies (10 papers) and Cytokine Signaling Pathways and Interactions (10 papers). Martin Hegen collaborates with scholars based in United States, Germany and Netherlands. Martin Hegen's co-authors include Cheryl Nickerson‐Nutter, James C. Keith, Mary Collins, Runyu Dong, Jean‐Baptiste Telliez, Chikao Morimoto, Bernhard Fleischer, Junichi Kameoka, S F Schlossman and James D. Clark and has published in prestigious journals such as Cell, Proceedings of the National Academy of Sciences and Journal of Biological Chemistry.

In The Last Decade

Martin Hegen

34 papers receiving 2.3k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Martin Hegen United States	26	992	900	761	376	274	35	2.3k
Esteban S. Masuda United States	33	384 0.4×	1.2k 1.4×	1.2k 1.5×	132 0.4×	84 0.3×	78	2.6k
Jenny Jongstra‐Bilen Canada	30	703 0.7×	1.3k 1.5×	1.5k 1.9×	82 0.2×	72 0.3×	47	2.8k
Harjit Dadi Canada	19	828 0.8×	868 1.0×	1.6k 2.0×	107 0.3×	145 0.5×	44	2.7k
Alexander Y. Tsygankov United States	30	939 0.9×	2.1k 2.3×	1.0k 1.4×	72 0.2×	116 0.4×	88	3.6k
Souad Rahmouni Belgium	24	332 0.3×	1.6k 1.7×	1.1k 1.4×	133 0.4×	125 0.5×	56	2.8k
Todd VanArsdale United States	27	1.4k 1.4×	1.7k 1.9×	1.0k 1.4×	93 0.2×	117 0.4×	48	3.7k
Hovav Nechushtan Israel	31	955 1.0×	1.5k 1.7×	874 1.1×	91 0.2×	45 0.2×	117	3.0k
Navin Rao United States	24	558 0.6×	1.3k 1.4×	1.1k 1.5×	172 0.5×	54 0.2×	43	2.9k
Wayne Pearce United Kingdom	24	808 0.8×	2.1k 2.3×	1.6k 2.0×	96 0.3×	65 0.2×	30	3.7k
Ed Croze United States	30	984 1.0×	581 0.6×	1.1k 1.4×	165 0.4×	48 0.2×	49	2.1k

Countries citing papers authored by Martin Hegen

Since Specialization

Citations

This map shows the geographic impact of Martin Hegen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Martin Hegen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Martin Hegen more than expected).

Fields of papers citing papers by Martin Hegen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Martin Hegen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Martin Hegen. The network helps show where Martin Hegen may publish in the future.

Co-authorship network of co-authors of Martin Hegen

This figure shows the co-authorship network connecting the top 25 collaborators of Martin Hegen. A scholar is included among the top collaborators of Martin Hegen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Martin Hegen. Martin Hegen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Gracey, Eric, Julie Coudenys, Tine Decruy, et al.. (2023). RORγt inhibition ameliorates IL-23 driven experimental psoriatic arthritis by predominantly modulating γδ-T cells. Lara D. Veeken. 62(9). 3169–3178. 18 indexed citations

Gerstenberger, Brian S., Mary Ellen Banker, James D. Clark, et al.. (2020). Demonstration of In Vitro to In Vivo Translation of a TYK2 Inhibitor That Shows Cross Species Potency Differences. Scientific Reports. 10(1). 8974–8974. 7 indexed citations

Pasricha, Trisha S., Thirumalai R. Ramalingam, Robert W. Thompson, et al.. (2019). Anti-IL-13Rα2 therapy promotes recovery in a murine model of inflammatory bowel disease. Mucosal Immunology. 12(5). 1174–1186. 33 indexed citations

Roeleveld, Debbie, Birgitte Walgreen, Monique M. Helsen, et al.. (2018). Imaging fibroblast activation protein to monitor therapeutic effects of neutralizing interleukin-22 in collagen-induced arthritis. Lara D. Veeken. 57(4). 737–747. 26 indexed citations

Verheul, Marije K., Jeroen N. Stoop, Bisheng Liu, et al.. (2017). Breach of autoreactive B cell tolerance by post-translationally modified proteins. Annals of the Rheumatic Diseases. 76(8). 1449–1457. 32 indexed citations

Mostafavi, Sara, Hideyuki Yoshida, Devapregasan Moodley, et al.. (2016). Parsing the Interferon Transcriptional Network and Its Disease Associations. Cell. 164(3). 564–578. 202 indexed citations

Stoop, Jeroen N., Bisheng Liu, Jing Shi, et al.. (2014). Antibodies Specific for Carbamylated Proteins Precede the Onset of Clinical Symptoms in Mice with Collagen Induced Arthritis. PLoS ONE. 9(7). e102163–e102163. 37 indexed citations

Kim, Kyung‐Hee, Andreas Maderna, Mark E. Schnute, et al.. (2011). Imidazo[1,5-a]quinoxalines as irreversible BTK inhibitors for the treatment of rheumatoid arthritis. Bioorganic & Medicinal Chemistry Letters. 21(21). 6258–6263. 48 indexed citations

Young, Deborah, Martin Hegen, Matthew J. Whitters, et al.. (2007). Blockade of the interleukin‐21/interleukin‐21 receptor pathway ameliorates disease in animal models of rheumatoid arthritis. Arthritis & Rheumatism. 56(4). 1152–1163. 238 indexed citations

10.

Hegen, Martin, Huiyuan Ma, Lee Napierata, et al.. (2007). IL-21 modulates cytokine levels in murine collagen-induced arthritis and contributes to disease pathology. Arthritis Research & Therapy. 9(Suppl 3). P1–P1. 1 indexed citations

11.

Hegen, Martin, Matthias Gaestel, Cheryl Nickerson‐Nutter, Lih‐Ling Lin, & Jean‐Baptiste Telliez. (2006). MAPKAP Kinase 2-Deficient Mice Are Resistant to Collagen-Induced Arthritis. The Journal of Immunology. 177(3). 1913–1917. 117 indexed citations

12.

Zhang, Yuhua, Jun Xu, Jeremy I. Levin, et al.. (2004). Identification and Characterization of 4-[[4-(2-Butynyloxy)phenyl]sulfonyl]-N-hydroxy-2,2-dimethyl-(3 S)thiomorpholinecarboxamide (TMI-1), a Novel Dual Tumor Necrosis Factor-α-Converting Enzyme/Matrix Metalloprotease Inhibitor for the Treatment of Rheumatoid Arthritis. Journal of Pharmacology and Experimental Therapeutics. 309(1). 348–355. 74 indexed citations

13.

Zhang, Yuhua, Martin Hegen, Jun Xu, et al.. (2004). Characterization of (2R, 3S)-2-({[4-(2-butynyloxy)phenyl]sulfonyl}amino)-N,3-dihydroxybutanamide, a potent and selective inhibitor of TNF-α converting enzyme. International Immunopharmacology. 4(14). 1845–1857. 48 indexed citations

14.

Pfisterer, Petra, et al.. (2002). A Subtractive Gene Expression Screen Suggests a Role of Transcription Factor AP-2α in Control of Proliferation and Differentiation. Journal of Biological Chemistry. 277(8). 6637–6644. 56 indexed citations

15.

Hegen, Martin, Junichi Kameoka, Rui-Ping Dong, Chikao Morimoto, & S F Schlossman. (1997). Structure of CD26 (Dipeptidyl Peptidase IV) and Function in Human T Cell Activation. Advances in experimental medicine and biology. 421. 109–116. 17 indexed citations

16.

Hegen, Martin, Junichi Kameoka, Runyu Dong, Stuart F. Schlossman, & Chikao Morimoto. (1997). Cross‐linking of CD26 by antibody induces tyrosine phosphorylation and activation of mitogen‐activated protein kinase. Immunology. 90(2). 257–264. 73 indexed citations

17.

Wu, Mei X., Z. Ao, Martin Hegen, C Morimoto, & S F Schlossman. (1996). Requirement of Fas(CD95), CD45, and CD11a/CD18 in monocyte-dependent apoptosis of human T cells. The Journal of Immunology. 157(2). 707–713. 32 indexed citations

18.

Hegen, Martin, et al.. (1993). Enzymatic Activity of CD26 (Dipeptidylpeptidase IV) is not Required for Its Signalling Function in T Cells. Immunobiology. 189(5). 483–493. 28 indexed citations

19.

Hegen, Martin, David Camerini, & Bernhard Fleischer. (1993). Function of Dipeptidyl Peptidase IV (CD26, Tp103) in Transfected Human T Cells. Cellular Immunology. 146(2). 249–260. 31 indexed citations

20.

Hegen, Martin, Gerald Niedobitek, Christophe Klein, H. Stein, & Bernhard Fleischer. (1990). The T cell triggering molecule Tp103 is associated with dipeptidyl aminopeptidase IV activity.. The Journal of Immunology. 144(8). 2908–2914. 155 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact